



FIG. 2A

LYMPHOCYTES




FIG. 2B

GRANULOCYTES




FIG. 2C

MONOCYTES






FIG. 2D

LYMPHOCYTES




FIG. 2E

GRANULOCYTES




FIG. 2F

MONOCYTES






FIG. 2G

LYMPHOCYTES




FIG. 2H

GRANULOCYTES




FIG. 2I

MONOCYTES






FIG. 2J

LYMPHOCYTES




FIG. 2K

GRANULOCYTES




FIG. 2L

MONOCYTES






FIG. 3A




FIG. 3B





FIG. 3C






FIG. 3D




FIG. 3E





FIG. 3F





App No.: 09/898,513
Title: Anti-CCR2 Antibodies and Methods...
Inventors: Gregory J. LaRosa, *et al.*

FIG. 3G




FIG. 3H





FIG. 3I





- 1C6 (anti CXCR3)
- 1D9 (anti CCR2b)

1D9 ($\mu\text{g/mL}$)		
	Value	Error
IC50	0.0037891	0.00062521
Hill	1.0185	0.15131
Bmax	105.63	2.6422
Bmin	11.518	1.9284
Chisq	280.01	NA
R	0.9948	NA




FIG. 4



- Control IgG2a
- 1D9 (anti-CCR2)

1D9 (anti-CCR2)		
	Value	Error
IC50	0.040086	0.0055353
Hill	2.0501	0.60845
Bmax	2762.3	52.391
Bmin	541.62	80.877
Chisq	2.9726e+05	NA
R	0.99056	NA

0.04 $\mu\text{g/mL} \approx 0.2 \text{ nM}$




FIG. 5





FIG. 6A




FIG. 6B